Ekso Bionics Announces New Clinical Trial Underway in Europe
(Thomson Reuters ONE) -
Moritz Klinik Launches Study to Evaluate Potential Benefits of Ekso GT(TM)
Robotic Exoskeleton for Stroke Rehabilitation
RICHMOND, Calif., Jan. 11, 2016 (GLOBE NEWSWIRE) -- Ekso Bionics Holdings, Inc.
(OTCQB:EKSO), a leading global robotic exoskeleton company, announced a new
randomized comparative clinical trial is currently underway in Europe. The trial
is called "The MOST Study" (Mobility improved after stroke when a robotic device
was used in comparison to physical therapy) and is being initialized by
Professor Dr. med. F. Hamzei, MD, MHBA, Chief physician of Department of
Neurological Rehabilitation, Moritz Klinik. This study is investigating the
impact of gait training with the Ekso GT(TM) on functional independence of 80
patients with impaired gait as a consequence of stroke, when compared to
conventional physiotherapy alone.
"Based on our early observation, gait training with Ekso GT has shown to be a
superior method over conventional physiotherapy techniques alone to improve
rehabilitation of stroke patients," said Professor Hamzei. "Stroke is one of the
most common causes of chronic disability and can have long term debilitating
effects. Intervening early and regularly with advanced assistive devices such as
Ekso GT may significantly positively impact stroke patients' overall motor
recovery and help to regain or maintain their independence. That's our
hypothesis in the ongoing randomized controlled study".
Early observations from clinical use of Ekso GT for rehabilitation of stroke
patients at Moritz Klinik led to the development of the MOST study. In this
study the Ekso GT will be used daily in one group, while in the control group
patients will be treated with conventional physiotherapy alone, in a daily
training program, over the course of three weeks. The level of functional
mobility will then be compared between both groups. The study is scheduled to
conclude mid-year 2017.
"Early research suggests that Ekso GT, with our smart Variable Assist software,
may help patients achieve better outcomes by providing an unparalleled
opportunity for early mobilization and high intensity gait therapy," said Thomas
Looby, president and chief commercial officer. "It is exciting to see these
early findings be the catalyst for a more significant study. We are pleased
this trial is underway and eager to see the results."
About Ekso Bionics
Ekso GT is a wearable bionic suit, which enables individuals with any amount of
lower extremity weakness to stand up and walk. The device helps patients re-
learn proper step patterns and weight shifts using a functional based platform.
Shifts in the users' weight activate sensors in the device, which initiate
steps. Battery-powered motors then move the legs, supporting the user as needed
to help them sustain balance and movement.
Since 2005, Ekso Bionics has been pioneering the field of robotic exoskeletons,
or wearable robots, to augment human strength, endurance and mobility. The
company's first commercially available product called Ekso has helped thousands
of people living with paralysis take millions of steps not otherwise possible.
By designing and creating some of the most forward-thinking and innovative
solutions for people looking to augment human capabilities, Ekso Bionics is
helping people rethink current physical limitations and achieve the remarkable.
Ekso Bionics is headquartered in Richmond, CA and is listed on the OTC QB under
the symbol EKSO. www.eksobionics.com
Forward-Looking Statements
Any statements contained in this press release that do not describe historical
facts may constitute forward-looking statements. Forward-looking statements may
include, without limitation, statements regarding (i) the plans and objectives
of management for future operations, including plans or objectives relating to
the design, development and commercialization of human exoskeletons, (ii) a
projection of financial results, financial condition, capital expenditures,
capital structure or other financial items, (iii) the Company's future financial
performance and (iv) the assumptions underlying or relating to any statement
described in points (i), (ii) or (iii) above. Such forward-looking statements
are not meant to predict or guarantee actual results, performance, events or
circumstances and may not be realized because they are based upon the Company's
current projections, plans, objectives, beliefs, expectations, estimates and
assumptions and are subject to a number of risks and uncertainties and other
influences, many of which the Company has no control over. Actual results and
the timing of certain events and circumstances may differ materially from those
described by the forward-looking statements as a result of these risks and
uncertainties. Factors that may influence or contribute to the inaccuracy of the
forward-looking statements or cause actual results to differ materially from
expected or desired results may include, without limitation, the Company's
inability to obtain adequate financing to fund the Company's operations and
necessary to develop or enhance our technology, the significant length of time
and resources associated with the development of the Company's products, the
Company's failure to achieve broad market acceptance of the Company's products,
the failure of our sales and marketing organization or partners to market our
products effectively, adverse results in future clinical studies of the
Company's medical device products, the failure to obtain or maintain patent
protection for the Company's technology, failure to obtain or maintain
regulatory approval to market the Company's medical devices, lack of product
diversification, existing or increased competition, and the Company's failure to
implement the Company's business plans or strategies. These and other factors
are identified and described in more detail in the Company's filings with the
SEC. To learn more about Ekso Bionics please visit us at www.eksobionics.com.
The Company does not undertake to update these forward-looking statements.
Media Contact:
Heidi Darling, Director of Marketing Communications
Phone: 510-984-1761 x317
E-mail: hdarling(at)eksobionics.com
Investor Contact:
Chad Rubin, Senior Vice President
Phone: 646-378-2947
E-mail: crubin(at)troutgroup.com
This announcement is distributed by GlobeNewswire on behalf of
GlobeNewswire clients. The owner of this announcement warrants that:
(i) the releases contained herein are protected by copyright and
other applicable laws; and
(ii) they are solely responsible for the content, accuracy and
originality of the information contained therein.
Source: Ekso Bionics via GlobeNewswire
[HUG#1977830]
Unternehmensinformation / Kurzprofil:
Datum: 11.01.2016 - 13:00 Uhr
Sprache: Deutsch
News-ID 443413
Anzahl Zeichen: 7469
contact information:
Town:
Richmond
Kategorie:
Business News
Diese Pressemitteilung wurde bisher 223 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"Ekso Bionics Announces New Clinical Trial Underway in Europe"
steht unter der journalistisch-redaktionellen Verantwortung von
Ekso Bionics (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
